1. Home
  2. GRF vs ATNM Comparison

GRF vs ATNM Comparison

Compare GRF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eagle Capital Growth Fund Inc.

GRF

Eagle Capital Growth Fund Inc.

N/A

Current Price

$10.20

Market Cap

41.0M

Sector

Finance

ML Signal

N/A

Logo Actinium Pharmaceuticals Inc. (Delaware)

ATNM

Actinium Pharmaceuticals Inc. (Delaware)

N/A

Current Price

$1.29

Market Cap

36.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GRF
ATNM
Founded
1989
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
41.0M
36.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GRF
ATNM
Price
$10.20
$1.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.50
AVG Volume (30 Days)
1.9K
237.7K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
3.70%
N/A
EPS Growth
N/A
14.17
EPS
1.16
N/A
Revenue
N/A
$90,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.80
N/A
Revenue Growth
N/A
11.11
52 Week Low
$9.50
$0.95
52 Week High
$11.85
$1.95

Technical Indicators

Market Signals
Indicator
GRF
ATNM
Relative Strength Index (RSI) 49.27 56.57
Support Level $9.60 $1.28
Resistance Level $10.61 $1.56
Average True Range (ATR) 0.16 0.09
MACD 0.03 -0.00
Stochastic Oscillator 63.76 44.11

Price Performance

Historical Comparison
GRF
ATNM

About GRF Eagle Capital Growth Fund Inc.

Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock, giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Share on Social Networks: